Efficacy of live attenuated and inactivated influenza vaccines among children in rural India: A 2-year, randomized, triple-blind, placebo-controlled trial
Open Access
- 29 April 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 18 (4), e1003609
- https://doi.org/10.1371/journal.pmed.1003609
Abstract
Influenza is a cause of febrile acute respiratory infection (FARI) in India; however, few influenza vaccine trials have been conducted in India. We assessed absolute and relative efficacy of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) among children aged 2 to 10 years in rural India through a randomized, triple-blind, placebo-controlled trial conducted over 2 years. In June 2015, children were randomly allocated to LAIV, IIV, intranasal placebo, or inactivated polio vaccine (IPV) in a 2:2:1:1 ratio. In June 2016, vaccination was repeated per original allocation. Overall, 3,041 children received LAIV (n = 1,015), IIV (n = 1,010), nasal placebo (n = 507), or IPV (n = 509). Mean age of children was 6.5 years with 20% aged 9 to 10 years. Through weekly home visits, nasal and throat swabs were collected from children with FARI and tested for influenza virus by polymerase chain reaction. The primary outcome was laboratory-confirmed influenza-associated FARI; vaccine efficacy (VE) was calculated using modified intention-to-treat (mITT) analysis by Cox proportional hazards model (PH) for each year. In Year 1, VE was 40.0% (95% confidence interval (CI) 25.2 to 51.9) for LAIV and 59.0% (95% CI 47.8 to 67.9) for IIV compared with controls; relative efficacy of LAIV compared with IIV was −46.2% (95% CI −88.9 to −13.1). In Year 2, VE was 51.9% (95% CI 42.0 to 60.1) for LAIV and 49.9% (95% CI 39.2 to 58.7) for IIV; relative efficacy of LAIV compared with IIV was 4.2% (95% CI −19.9 to 23.5). No serious adverse vaccine-attributable events were reported. Study limitations include differing dosage requirements for children between nasal and injectable vaccines (single dose of LAIV versus 2 doses of IIV) in Year 1 and the fact that immunogenicity studies were not conducted. In this study, we found that LAIV and IIV vaccines were safe and moderately efficacious against influenza virus infection among Indian children. Clinical Trials Registry of India CTRI/2015/06/005902.Funding Information
- US Centers for Disease Control and Prevention (U01IP000492)
This publication has 26 references indexed in Scilit:
- Epidemiology of acute respiratory infections in children - preliminary results of a cohort in a rural north Indian communityBMC Infectious Diseases, 2015
- Dynamics of Influenza Seasonality at Sub-Regional Levels in India and Implications for Vaccination TimingPLOS ONE, 2015
- Incidence of influenza-associated hospitalization in rural communities in western and northern India, 2010–2012: A multi-site population-based studyJournal of Infection, 2015
- Influenza seasonality and vaccination timing in tropical and subtropical areas of southern and south-eastern AsiaBulletin of the World Health Organization, 2014
- Dynamic Patterns of Circulating Seasonal and Pandemic A(H1N1)pdm09 Influenza Viruses From 2007–2010 in and around Delhi, IndiaPLOS ONE, 2012
- Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysisThe Lancet, 2011
- Design and Performance of the CDC Real-Time Reverse Transcriptase PCR Swine Flu Panel for Detection of 2009 A (H1N1) Pandemic Influenza VirusJournal of Clinical Microbiology, 2011
- The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adultsInfluenza and Other Respiratory Viruses, 2010
- Efficacy of a single dose of live attenuated influenza vaccine in previously unvaccinated children: A post hoc analysis of three studies of children aged 2 to 6 yearsClinical Therapeutics, 2009
- Modelling survival dataPublished by Springer Science and Business Media LLC ,1994